title: Use of combination therapy for dyslipidemia: a lipid clinic approach.
abstract: Combination drug therapy has been used in the management of dyslipidemia by lipid clinics since the early 1980s. The explosion of statin use in the early and mid-1990s has caused a shift to monotherapy for dyslipidemia. However, the use of combination therapy has reemerged as a treatment option for patients who have elevated triglyceride and low-density lipoprotein (LDL) cholesterol levels as more attention is now focused on non-high-density lipoprotein cholesterol. This article discusses the use of combination therapy in a lipid clinic based on experiences from a multisite clinical practice of >48 physicians and 80,000 patients. Approaches to LDL lowering for complex dyslipidemias and management strategies for specific lipid-lowering therapies are provided.
authors.affiliation: Midwest Heart Specialists Disease Prevention Center, Naperville, Illinois 60540, USA. abrown@midwestheart.com
authors.forename: Alan S
authors.initials: AS
authors.lastname: Brown
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001384:Azetidines / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D009525:Niacin / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D014280:Triglycerides; D009525:Niacin; D000069438:Ezetimibe